細(xì)胞名稱

人結(jié)腸腺癌細(xì)胞SW48

貨物編碼

BFN60808301

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細(xì)胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運(yùn)輸方式

常溫保溫運(yùn)輸

干冰運(yùn)輸

安全等級

1

用途限制

僅供科研        1類

培養(yǎng)體系

90%DMEM+10%FBS+1%雙抗 

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人結(jié)腸腺癌細(xì)胞SW48取自85歲女性供體，該細(xì)胞源于ATCC

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).

Part of: MD Anderson Cell Lines Project.

From: Scott and White Clinic; Temple; USA.

Doubling time: 70 hours, at 63th passage (PubMed=1000501); 33 hours (PubMed=25984343).

Microsatellite instability: Instable (MSI-high) (PubMed=9000572; PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger).

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative phosphoproteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: N-glycan profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

基因突變

Homozygous for ACVR2A p.Lys437fs*5 (c.1310delA) (PubMed=12615714).

APC p.Arg2714Cys (c.8140C>T) (PubMed=24755471).

Heterozygous for B2M p.Ser14fs*29 (c.41_44delCTCT) and p.Glu67fs (c.200delA) (PubMed=8197130).

Heterozygous for CTNNB1 p.Ser33Tyr (c.98C>A) (PubMed=9294210; PubMed=24755471; ATCC).

Homozygous for TGFBR2 p.Lys128Serfs*35 (c.383delA) (PubMed=12615714).

Has no TP53 mutation (PubMed=16418264).

HLA信息

/

STR信息

Amelogenin        X

CSF1PO        9,10

D3S1358        13,14,15

D5S818        10,14

D7S820        9,10

D8S1179        13,14,15

D13S317        11,12

D16S539        11,13

D18S51        13

D21S11        28,31

FGA        20

Penta D        10

Penta E        12,13

TH01        6,9.3

TPOX        8

vWA        18,20,21 (AddexBio; ATCC)

18,20 (Cosmic-CLP; ECACC; PubMed=25877200; PubMed=25926053)

參考文獻(xiàn)

PubMed=29101300; DOI=10.15252/msb.20177701

Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R., Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S., Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J., Weichert W., Knapp S., Feller S.M., Kuster B.

Pharmacoproteomic characterisation of human colon and rectal cancer.

Mol. Syst. Biol. 13:951-951(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023

Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.

Quantitative proteomics of the Cancer Cell Line Encyclopedia.

Cell 180:387-402(2020)